anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In patients on peritoneal dialysis, the cutaneous emergency (exit-site) represents a potential access route to the peritoneum; consequently, it can become a site for microbial infections. These infections, initially localized to the exit-site, may spread to the peritoneum causing peritonitis, which is the most common cause of drop-out from peritoneal dialysis and transition to hemodialysis. Peritoneal catheters have dacron caps which have the function of counteracting the traction of the catheter itself and at the same time acting as a barrier for microorganisms, preventing the spread towards the peritoneum. Despite this, the same dacron cap can represent a sort of nest for microorganisms to colonize and, with the formation of a biofilm that facilitates their proliferation, make the same organisms impervious to antibiotic therapy and even resistance to them. The most effective tool for monitoring the health status of the exit-site is represented by the objective examination. This examination, through the use of well-defined scales, helps to provide a pathological score of the exit, facilitating the implementation of necessary precautions. In the presence of recurrent exit-site infections, from both Gram positive and Gram negative bacteria, minimally invasive surgical therapy is a valid approach to break this vicious circle. It helps avoid subjecting the patient to the removal of the peritoneal catheter, temporary transition to hemodialysis with the insertion of a central venous catheter, and subsequent repositioning of another peritoneal catheter. We propose the case of a recurrent Staphylococcus Aureus infection resolved after cuff shaving of the exit-site.
All patients will receive rituximab sc on days 1, 8, 15 and 22. Interim staging will be performed around day 50. After interim staging, patients will be considered low-risk if they reached a complete remission with the first 4 applications of rituximab monotherapy or if they reached a partial remission and had a baseline IPI of 0, 1 or 2. Patients considered low-risk will receive rituximab sc consolidation.
Rabeprazole belongs to a class of antisecretory compounds (substituted benzimidazole proton-pump inhibitors) that do not exhibit anticholinergic or histamine H2-receptor antagonist properties, but suppress gastric acid secretion by inhibiting the gastric H+, K+ATPase at the secretory surface of the gastric parietal cell. Because this enzyme is regarded as the acid (proton) pump within the parietal cell, rabeprazole has been characterized as a gastric proton- pump inhibitor. Rabeprazole blocks the final step of gastric acid secretion.

In gastric parietal cells, rabeprazole is protonated, accumulates, and is transformed to an active sulfenamide. When studied in vitro, rabeprazole is chemically activated at pH 1.2 with a half-life of 78 seconds. It inhibits acid transport in porcine gastric vesicles with a half-life of 90 seconds.
Subjects will receive a glimepiride capsule, 2, 4 or 6 mg, once daily for the duration of the study. Subjects will continue taking metformin and receive placebo for bexagliflozin for the duration of the study.
A traditional Chinese medicine biological characteristic method capable of producing various stem cells in a human body, can improve anemia, severe anemia, leukemia early stage and various leukemia related symptoms. The effective number, quality and functions of various cells in the human body can be increased. Related cancer cells and tumor cells can be restricted and cleared. The method has roles in softening hard mass and freeing gate and promoting blood circulation to remove blood stasis. The method has relatively good treatment effects on male sperm no-production, dead sperms and fewer sperms, and female dysmenorrhea, amenorrhea, no oviposition or less oviposition. Patients who need bone marrow transplantation and stem cell transplantation and cannot be matched or be unsuccessfully yet matched can be conservatively treated, and a certain or relatively satisfactory effect can be produced. The method can also be applied to adjuvant therapy of patients with various types of bone marrow transplantation and stem cell transplantation.
We investigated the potential correlation between miR-223 and NAcHT, LRR, and PYd domain-containing protein 3 (NLRP3) in the context of renal ischemia-reperfusion injury (RIRI), which is a leading cause of acute renal failure with significant mortality rates. Additionally, miR-223 has been implicated in renal inflammation, further highlighting its relevance to this study. C57BL/6 male mice were used as RIRI models. After successful modeling, pathological examinations and serum creatinine and miR-223 levels were tested. Pro-inflammatory cytokine (IL-1β, IL-6, IL-8, NLPR3, TLR4) expression was detected in mice by western blot (kidney tissue) and enzyme-linked immunosorbent assay (serum). HK-2 cells were used for in vitro experiments. A hypoxia/reoxygenation (H/R) model was used, and miR-223 and pro-inflammatory cytokine levels were detected using PCR and western blot assays, respectively. A dual-luciferase reporter assay was conducted to confirm the binding of miR-223 to NLPR3. Next, NLRP3 was knocked down to determine whether the anti-inflammatory function of miR-223 is dependent on NLRP3. MiR-223 expression was lower in RIRI mice than in the sham operation group. The level of miR-223 negatively correlated with serum creatinine levels and the severity of tubule injury. Increased proinflammatory cytokine levels in RIRI mice were observed. In vitro, miR-223 alleviated the inflammatory response in H/R treated cells by inhibiting proinflammatory cytokines. Dual-luciferase reporter and western blot assays confirmed the binding of miR-223 to NLRP3. NLRP3 knockdown reversed the anti-inflammatory effects of miR-223 in HK-2 cells. MiR-223 plays an anti-inflammatory role in RIRI by targeting NLRP3 to repress pro-inflammatory factors.
The present invention discloses a medicine for treating functional uterine bleeding. The present invention is prepared by that traditional Chinese medicines such as red peony root, motherwort herb, notoginseng, hairyvein agrimonia herb, carbonized sanguisorba root and charred pollen typhae are used as raw materials and are made into capsules by extraction, concentration, drying and filling according to the different properties of all the traditional Chinese medicines. The medicine of the present invention has the efficiency of cooling blood, expelling stasis, stop bleeding and regulating menstruation. The present invention mainly treats the uterine bleeding caused by blood heat and stasis, for example, symptoms such as menoxenia, large menstrual blood volume or menostaxis, deep red or violet red of menstrual blood, viscous menstrual blood, menstrual blood with blood clots, swelling abdominal pain refusing to pressure, pain alleviation below blood clots, vertigo, blush, polydipsia, cool drink flavor, constipation, yellow urine, darkish red tongue quality, tongue quality with petechia, yellow tongue furs, astringent pulse. The present invention is suitable for people who have functional uterine bleeding and the symptoms. By the indication of a pharmacodynamic test, the medicine of the present invention has the functions of hemoglutination promotion and hemostasis and has no toxic or side effect.
A food for preventing life style-related diseases which contains a mung bean protein digestion product. This mung bean protein digestion product can be obtained by hydrolyzing mung bean-origin protein with a protease. It is preferable that the content of dipeptides or tripeptides in the total peptides in the mung bean protein digestion product amounts to 10% or above. The food for preventing life style-related diseases as described above is suitable for preventing, in particular, hypertension, arteriosclerosis, obesity and so on. It is also intended to provide an anti-hypertensive drug, an anti-atherogenic drug, a blood vessel thickening inhibitor and an anti-obesity drug containing the mung bean protein digestion product as described above. It is furthermore intended to provide a diet food containing the mung bean protein digestion product. Because of being obtained from a material originating in a natural substance that has been taken for a long time, the mung bean protein digestion product has little side effects and a high safety. Moreover, it can be produced from a by-product obtained in the process of producing bean-starch vemicelli (Harusame). Thus, it is nondetrimental to the environment and expected as contributing to the recycle-based society.
PURPOSE:To provide an adriamycin resistance-dissolving medicine containing a specified compound having a base skeleton composed of tyrosine as the active component, capable of overcoming adriamycin resistance and amplifying the effect of adriamycin. CONSTITUTION:An adriamycin(ADM) resistance-dissolving medicine containing a compound of formula I [R1 is 5-isoquinolyl or p-aminoethyloxyphenyl; R2 and R3 are each H or methyl; (n) is 2 or 3: R4 is benzyloxycarbonyl or 3- phenylpropionyl] or its pharmaceutically permissible acid adduct as the active component. The compound of formula I, is exemplified by e.g. N-[2-(4- benzyloxycarbonylpiperazino)-1-(p-methoxybenzyl)ethyl]-N-methyl-p-2- aminoethyloxybenzenesulonic acid amide. The compound of formula I, e.g. a compound of formula II can be obtained by reacting tyrosine of formula III with piperazine and then carrying out condensation reaction between the resultant compound of formula IV and isoquinolinesulfonic acid chloride.
Sulphates of estrone, equilenin, equilin, b -estradiol, a - and b -dihydroequilenin are prepared from pregnant mares' urine by preparing a concentrate which is dissolved in an aqueous medium and salted out with an inorganic salt, e.g. sodium and potassium salts of sulphuric, phosphoric or hydrochloric acid.ALSO:Estrogen compositions which may be administered orally, topically or by intra-venous injection, are prepared from pregnant mares' urine by preparing a concentrate which is dissolved in an aqueous medium and salting out the solution with an inorganic salt, removing the precipitate and separating the estrogens from inorganic salt therein.  Specified inorganic salts are the alkali metal, preferably sodium and potassium, salts of sulphuric, phosphoric or hydrochloric acids.  The precipitate may be extracted with an aliphatic ketone, such as acetone or methyl ethyl ketone, containing a small amount of an alcohol, such as methanol, ethanol, isopropanol or butanol.  Finally water may be added to the solution and the product concentrated so as to remove solvent leaving a concentrated aqueous solution.  Buffers (many specified) may be added to maintain pH 6.5-7.5.  Specified carriers and drying agents are dextrose, galactose, pectin, gelatine, dextran, polyvinylpyrrolidone and preferably lactose. Specified estrogens present are the sulphates of estrone, equilin, equilenin, b -estradiol, a - and b -dihydroequilenin.
Large randomized trials in sepsis have generally failed to find effective novel treatments. This is increasingly attributed to patient heterogeneity, including heterogeneous cardiovascular changes in septic shock. We discuss the potential for machine learning systems to personalize cardiovascular resuscitation in sepsis. While the literature is replete with proofs of concept, the technological readiness of current systems is low, with a paucity of clinical trials and proven patient benefit. Systems may be vulnerable to confounding and poor generalization to new patient populations or contemporary patterns of care. Typical electronic health records do not capture rich enough data, at sufficient temporal resolution, to produce systems that make actionable treatment suggestions. To resolve these issues, we recommend a simultaneous focus on technical challenges and removing barriers to translation. This will involve improving data quality, adopting causally grounded models, prioritizing safety assessment and integration into healthcare workflows, conducting randomized clinical trials and aligning with regulatory requirements.
Participants will receive the e- and mHealth intervention 'MyPlan 2.0' without the three behaviour change techniques of interest (action planning, coping planning, self-monitoring). They will receive general tips and tricks and other behaviour change techniques included in the intervention: tailored feedback and eliciting social support.
Acute ischemic stroke (AIS) is a leading cause of death and long-term disability in the Western world. Catheter-based removal of blood clots (endovascular therapy-EVT) is now the standard of care for AIS caused by large vessel occlusions in the brain. The level of blood pressure during the procedure appears to influence outcome. However, optimal blood pressure management strategy has not been determined. Current blood pressure management strategy during EVT typically aims to maintain blood pressure above or within predefined fixed targets and is based on observational data and expert consensus rather than on high-quality randomized evidence. Should blood pressure during removal of the occlusion be managed according to the patient's individual blood pressure level or according to predefined fixed blood pressure targets? The primary aim of this pilot trial is to determine whether randomization to a procedure strategy targeting a predefined mean arterial blood pressure (MABP) of 70-90 mmHg versus an individual strategy targeting ± 10 % of a MABP reference value is feasible. Secondary aims are to test recruitability and to detect challenges or obstacles that would call for changes in the study design.
An antibiotic active against M. tuberculosis var. hominis is obtained by extracting E. coli with a strong solvent for lipids, removing the solvent and treating the extracts so as to remove firstly components soluble in water of pH 8 to 9 and secondly components soluble in water of pH 7 or less.  The bacterial mass obtained by centrifuging a culture broth is extracted preferably after grinding with sodium chloride, sodium sulphate or solid carbon-dioxide.  Extraction is by means of (a) a strong solvent for lipids followed by a weak solvent for lipids; (b) a weak followed by a strong solvent for lipids; or (c) partition between a mixture of strong and weak solvents for lipids.  Specified as strong solvents for lipids are (a) the water-immiscible solvents ether, petroleum ether and hydrocarbons, chlorinated hydrocarbons, e.g. methylene chloride and esters, e.g. ethyl acetate; and (b) the water-miscible solvents acetone, alcohols, e.g. ethanol and butanol and pyridine, in the anhydrous form or containing a specified amount of water.  Weak solvents for lipids are alcohols and ketones containing at least 40 per cent of water, except in the case of partitioning with strong solvents for lipids when the weak solvent for lipids need contain only 5 to 25 per cent water. After removal of solvent, the extract is treated with aqueous alkali e.g. potassium hydroxide of pH 8 to 9 followed by acidification to precipitate the antibiotic which may be recrystallized from petroleum ether.
ABSTRACT OF THE DISCLOSURE           A continuous clear surfaced web adapted to be fed from a supply roll thereof for a converting operation thereon is preprinted with n succession of identical repeat patterns extend-ing over the entire width of the web.   Each pattern consists of areas which contain printed matter and at least one longitudinable discontinuous area or segment which, except for the presence of a printed register mark therein, is clear and unprinted.   A photo sensitive scanner is directed at the register mark track of the feeding web for detecting the register marks and controlling in accordance therewith the timing of an associated machine operation, such as web splicing, so as to be performed in register with the web pattern.  The operation of the scanner is controlled by a digital reset counter of pulses fed from a pulse generator driven by the seb feeding mechanism.   The counter is reset to zero upon the detection of each register mark.   It is initially preset to a number during the count of which the scanner is deactivated and after the count of which the scanner is activated.   The number preset in the counter corresponds to the length of the register mark track starting from one register mark and continuing up to the segment of clear track containing the next register mark. The counter thus gates the operation of the scanner so as to detect only register marks and not to misread other printed matter lying in the scanned track as a register mark.
INTRODUCTION: Current traveller health surveillance is 'top-down'. Mobile-based surveillance could capture infection symptoms in real time. We aimed to evaluate the spectrum of illness in travellers using a mobile app-based system.
METHODS: This study (ClinicalTrials.gov NCT04672577) used an application called Infection Tracking in Travellers (ITIT) that records travel-related illness symptoms with associated geolocation and weather data. The free ITIT app is available in 14 languages. Participants were recruited globally from April 2022 to July 2023. Participants >18 years of age travelled internationally and provided electronic consent. Incentives included the provision of travel health information imported from the WHO website. Symptoms were recorded with daily pop-up questionnaires and symptom severity was assessed using a Likert scale. Two post-travel questionnaires were administered. Logistic mixed models examined factors relating to symptom presence, and a random forest model examined symptom impact.
RESULTS: 609 participants were recruited until July 2023. Participants had an average age of 37 years (18-79), and an average travel duration of 26 days (2-281). Most participants were travelling for leisure/tourism (401; 66%), followed by 'visiting friends and relatives' (99; 16%) and business travel (80; 13%). All continents were visited by at least one traveller. Of 470 registered trips, symptoms were reported on 163 trips (35%). Gastrointestinal symptoms were reported on 87 trips (19%) and respiratory symptoms on 81 trips (17%). The most important factors in predicting the presence of symptoms were duration of travel, travelling in winter and high humidity. Diarrhoea, headache and nausea were symptoms with most impact on daily activities. Post-travel questionnaires showed that 12% of surveyed participants experienced symptoms with several episodes of self-treatment. Two diagnoses were recorded: Lyme disease and amoebic dysentery.
CONCLUSION: The digital tool ITIT successfully captures the spectrum of travel-related illness. This detailed epidemiology is crucial for outbreak detection and for the formulation of travel medicine guidelines.
TRIAL REGISTRATION NUMBER: NCT04672577.
<P>PROBLEM TO BE SOLVED: To obtain a preventing agent for contact dermatitis derived from plant extracts having antimicrobial actions on bacteria related to development and aggravation of the contact dermatitis and inhibitory actions on enzymes in combination, and to obtain various kinds of products utilizing the preventing agent for the contact dermatitis.  <P>SOLUTION: The preventing agent for the contact dermatitis comprises the extracts from one or more species of plants selected from the group consisting of Daucus carota L. var. sativa DC, Aspidistra elatior Bl., Sapindus mukurossi Gaertn., Apium graveolens L. var. dulce DC, Alpinia galanga (L.) Swarts and Lithospermum erythrohizon Sieb. et Zucc. as an active ingredient. The preventing agent for the contact dermatitis has the antimicrobial actions on bacteria indigenous to the skin or feces and inhibitory actions on the enzymes in combination as functions to prevent the contact dermatitis. A textile product or a film product comprises the preventing agent for the contact dermatitis. An absorbing article or a wiper uses the textile product or the film product. A skin care preparation for external use is obtained by formulating the preventing agent for the contact dermatitis.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
A method and article for delivery of skin care agents. Freeze-dried liposomes are used to encapsulate agents for delivery to specific cells in the skin. The applicable agents include perfumes, moisturizers, vitamins and therapeutic compounds as well as others. The agents are encapsulated in liposomes specifically selected to carry the agents to the target cells thereby increasing effectiveness and efficiency and minimizing systemic absorption. The liposomes are at least partially freeze-dried to improve shelf-life and improve delivery to the skin. After freeze-drying, the liposomes are deposited on or in a fabric-like pad. The liposomes are rehydrated either immediately prior to application to the skin or on the skin using natural moisture or a hydrating solution. An applicator is also provided to secure and hold the impregnated pad during use. The applicator may provide steam or vapor to rehydrate the liposomes during application.
Pregnancy Category C

Difluprednate has been shown to be embryotoxic (decrease in embryonic body weight and a delay in embryonic ossification) and teratogenic (cleft palate and skeletal anomalies) when administered subcutaneously to rabbits during organogenesis at a dose of 1 to 10 mcg/kg/day. The no-observed-effect-level (NOEL) for these effects was 1 mcg/kg/day and 10 mcg/kg/day was considered to be a teratogenic dose that was concurrently found in the toxic dose range for fetuses and pregnant females. Treatment of rats with 10 mcg/kg/day subcutaneously during organogenesis did not result in any reproductive toxicity, nor was it maternally toxic. At 100 mcg/kg/day after subcutaneous administration in rats, there was a decrease in fetal weights and delay in ossification, and effects on weight gain in the pregnant females. It is difficult to extrapolate these doses of difluprednate to maximum daily human doses of DUREZOL, since DUREZOL is administered topically with minimal systemic absorption, and difluprednate blood levels were not measured in the reproductive animal studies. However, since use of difluprednate during human pregnancy has not been evaluated and cannot rule out the possibility of harm, DUREZOL should be used during pregnancy only if the potential benefit justifies the potential risk to the embryo or fetus.
This is a single arm pilot study to evaluate the technical feasibility and safety of performing DEB-TACE using the investigational delivery device: Surefire Infusion System (SIS). Patients presenting with primary liver cancer without evidence of metastatic disease or vascular invasion will be considered for the trial. Patients enrolled in the trial will undergo 1 or 2 sessions of DEB-TACE delivered through SIS as determined by the performing interventional radiologist. Decision for second treatment will be based on the degree of disease burden and vascular anatomy demonstrated on the first treatment session. To limit potential hepatotoxicity, patients with multifocal disease in a single lobe may be treated with a 2nd treatment with the investigational device. Patients with a large lesion being supplied by multiple vessels may also undergo a 2nd treatment session based on the investigator's judgement. The decision to proceed with a second treatment will be determined at the time of the first treatment based on disease burden and vascular anatomy. There will be an interval of 2-4 weeks between treatments. All patients undergoing 2nd treatment will have a repeat laboratory evaluation with treatment deferred for 2-4 weeks for those not meeting initial inclusion criteria. For patients who labs have not normalized at this time will not undergo a 2nd treatment.